anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Cholecalciferol
Trial phase: Phase 2 | Phase 3
ATC code: A11CC05 | A11CC55 | M05BB03 | M05BB04 | M05BB05 | M05BB07 | M05BB08 | M05BB09 | M05BX53
SMILES: [H][C@@]12CC[C@]([H])([C@H](C)CCCC(C)C)[C@@]1(C)CCC/C2=C\C=C1\C[C@@H](O)CCC1=C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 274
Group description: Patient demographics of patients receiving study drug
Eligibility criteria:
Inclusion Criteria:

Patients >18 years of age
Patients admitted to the neurosurgery or neurology services
Patients admitted to a critical care unit
Informed consent
Expected to stay in the ICU for 48 hours or more
Vitamin D deficiency (<20ng/mL)

Exclusion Criteria:

Patients where a vitamin D level was not drawn within 48 hours of admission
Patients not randomized within 48 hours of admission
Readmitted patients to the critical care unit
Lack of informed consent
Prior supplementation with vitamin D
Severely impaired gastrointestinal function
Other trial participation
Pregnant or lactating women
Hypercalcemia (total calcium of >10.6 mg/dL or ionized serum calcium of >5.4 mg/dL
Tuberculosis history or clinical exam
Sarcoidosis history or clinical exam
Nephrolithiasis within the prior year
Patients not deemed suitable for study participation (ie, psychiatric disease, living remotely from the clinic, or prisoner status)
Pregnant or nursing women
Intervention: Tyrosine
Trial phase: Not Applicable
SMILES: N[C@@H](Cc1ccc(O)cc1)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 85
Group description: Hydroxyethyl starch 6% (130/0.4) solution during surgery

Hydroxyethyl starch: 6% Hydroxyethyl starch 130/0.4 during surgery
Eligibility criteria:
Inclusion Criteria:

Age 40 - 85 years old
Scheduled for elective aortic valve replacement with or without coronary artery bypass grafting with or without additional minor surgical procedure.
Written, informed consent for participation in this investigation.

Exclusion Criteria:

Patients with Raynaud's disease or other disease associated with upper extremity vascular insufficiency,
Inability to perform EndoPAT exam (inability to lie still for 15 min, or significant finger deformity),
Patients with renal failure with oliguria or anuria not related to hypovolemia.
Patients receiving dialysis.
Patients with preoperative renal insufficiency (Creatinine > 1.6 mg/dL)
Anticipated deep hypothermic circulatory arrest
Known hypersensitivity or allergy to hydroxyethyl starch or the excipients of hydroxyethyl starch
Clinical conditions with volume overload (e.g., patients in pulmonary edema or congestive heart failure)
Patients with severe hypernatremia or severe hyperchloremia
Patients with intracranial bleeding
Pregnant or breast feeding women
Critically ill adult patients, including patients with sepsis, due to increased risk of mortality and renal replacement therapy, (e.g. patients who are hospitalized in the intensive care unit prior to surgery)
Severe liver disease
Pre-existing coagulation or bleeding disorders
Any contraindications to proposed interventions.
Intervention: Bupivacaine
Trial phase: Not Applicable
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 23
Group description: Subjects will receive single shot local anesthetic, 30 ml bolus of bupivacaine, given preoperatively to help with postoperative pain

30ml bolus of bupivacaine: Local anesthetic
Eligibility criteria:
Inclusion Criteria:

Adult patients18 years and older scheduled for hip arthroscopy surgery
American Society of Anesthesiologists (ASA) physical status I -III
Mentally competent and able to give consent for enrollment in the study

Exclusion Criteria:

Chronic opioid use (use of any opioid daily or on most days of the week for more than 3 months)
Diagnosed peripheral neuropathy in the surgical lower extremity
Allergy to study medications
BMI >42
Intervention: Bupivacaine
Trial phase: Not Applicable
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 25
Group description: Subjects will receive single shot local anesthetic, 30 ml bolus of bupivacaine, given preoperatively to help with postoperative pain

30ml bolus of bupivacaine: Local anesthetic
Eligibility criteria:
Inclusion Criteria:

Adult patients18 years and older scheduled for hip arthroscopy surgery
American Society of Anesthesiologists (ASA) physical status I -III
Mentally competent and able to give consent for enrollment in the study

Exclusion Criteria:

Chronic opioid use (use of any opioid daily or on most days of the week for more than 3 months)
Diagnosed peripheral neuropathy in the surgical lower extremity
Allergy to study medications
BMI >42
Intervention: Ambrisentan
Trial phase: Phase 4
ATC code: C02KX02 | C02KX52
SMILES: COC(c1ccccc1)(c1ccccc1)[C@H](Oc1nc(C)cc(C)n1)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1
Group description: Subjects will be switching treatments from Bosentan (Tracleer) to Ambrisentan (Letairis)

Ambrisentan: At entry to the study following the screen visits, patients will be switched from bosentan to ambrisentan to complete a 24 week trial. The only study intervention will be ambrisentan.
Eligibility criteria:
Inclusion Criteria:

Diagnosis of a Connective Tissue Disease (CTD)
Age range: 18-80 years old
Previous Right Heart Catheterization (RHC) demonstrating PAH
Forced vital capacity (FVC) greater than 50%
Carbon Monoxide Diffusing Capacity (DLCO) greater than 50%
World Health Organization (WHO) functional class II or III
Able to perform a 6 minute walk test (6MWT)
Stable dose of antihypertensive medications
Non-pregnant females
Have to be currently on stable dose of bosentan for at least 3 months
Adequate acoustic images to allow for transthoracic echocardiography to be performed

Exclusion Criteria:

Exercise limitation related to a non-cardiopulmonary reason (e.g. arthritis)
Severe systemic hypertension greater than 170/95
Patients with a prior history of cardiovascular disease
WHO functional class IV status
Patients with severe other organ disease felt by investigators to impact on survival during the course of the study.
FVC less than 50% of predicted
DLCO less than 50% of predicted
Intervention: Ambrisentan
Trial phase: Phase 4
ATC code: C02KX02 | C02KX52
SMILES: COC(c1ccccc1)(c1ccccc1)[C@H](Oc1nc(C)cc(C)n1)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 2
Group description: Subjects will be switching treatments from Macitentan (Opsumit) to Ambrisentan (Letairis)

Ambrisentan: At entry to the study following the screen visits, patients will be switched from bosentan to ambrisentan to complete a 24 week trial. The only study intervention will be ambrisentan.
Eligibility criteria:
Inclusion Criteria:

Diagnosis of a Connective Tissue Disease (CTD)
Age range: 18-80 years old
Previous Right Heart Catheterization (RHC) demonstrating PAH
Forced vital capacity (FVC) greater than 50%
Carbon Monoxide Diffusing Capacity (DLCO) greater than 50%
World Health Organization (WHO) functional class II or III
Able to perform a 6 minute walk test (6MWT)
Stable dose of antihypertensive medications
Non-pregnant females
Have to be currently on stable dose of bosentan for at least 3 months
Adequate acoustic images to allow for transthoracic echocardiography to be performed

Exclusion Criteria:

Exercise limitation related to a non-cardiopulmonary reason (e.g. arthritis)
Severe systemic hypertension greater than 170/95
Patients with a prior history of cardiovascular disease
WHO functional class IV status
Patients with severe other organ disease felt by investigators to impact on survival during the course of the study.
FVC less than 50% of predicted
DLCO less than 50% of predicted
Intervention: ALBUTEROL
Trial phase: Phase 3
ATC code: R03AC02 | R03AK04 | R03AK13 | R03AL02 | R03CC02
SMILES: CC(C)(C)NCC(O)c1ccc(O)c(CO)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 30
Group description: 2.5 mg inhaled albuterol through a high efficiency nebulizer -single dose

Albuterol: : Experimental: Inhaled albuterol

2.5 mg inhaled albuterol through a high efficiency nebulizer as a single dose
Eligibility criteria:
Inclusion Criteria:

Heart Failure with Preserved Ejection Fraction (HFpEF)
Normal left ventricular ejection fraction (≥50%)
Elevated Left Ventricular filling pressures at cardiac catheterization (defined as resting Pulmonary Capillary Wedge Pressure>15 mmHg and/or ≥25 mmHg during exercise).

Exclusion Criteria:

Prior albuterol therapy (within previous 48 hours)
Current long acting inhaled beta agonist use
Significant hypokalemia (<3meq/L)
Significant valvular disease (>moderate left-sided regurgitation, >mild stenosis)
High output heart failure
Severe pulmonary disease
Unstable coronary disease
Constrictive pericarditis
Restrictive cardiomyopathy
Hypertrophic cardiomyopathy
Intervention: Morphine
Trial phase: Phase 4
ATC code: A07DA52 | N02AA01 | N02AA51 | N02AG01
SMILES: [H][C@@]12C=C[C@H](O)[C@]3([H])Oc4c(O)ccc5c4[C@]13CCN(C)[C@]2([H])C5
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 16
Group description: Intrathecal solution has only an opioid (hydromorphone, fentanyl or morphine) and no bupivacaine. Patients will administer PTM bolus of opioid without bupivacaine. This opioid bolus dose would be the same as they would have received prior to enrolling in the study (with bupivacaine). The bolus will be administered over 2 minutes and will have a variable frequency depending on patient's need but the number of boluses should be >2 and <10.

Opioid: Patient-activated intrathecal bolus for incident pain

Patients received Opioid only for 7 days, either in the first 7 days or last 7 days of the study. Bolus delivery was locked out after each medication change for one to two days. Data were collected on days 4-7 and days 11-14.
Eligibility criteria:
Inclusion Criteria

Age more than 30 years implanted with an intrathecal drug delivery device.
Intrathecal pump patients on stable dose for the last 3 months.
Using on average more than 2 and less than 10 PTM doses per day
Intrathecal medication admixture consisting of bupivacaine and another opioid (fentanyl or hydromorphone or morphine)

Exclusion Criteria

Using 10 or more PTM bolus doses per day or 2 or less PTM bolus doses per day
Pending litigation or worker compensation claim
Any recent (less than 3 month) procedures in spine (surgeries) or catheter adjustments.
Recent pump dose adjustment within the past 3 months
Pumps with medications other than bupivacaine/opioid combination.
Pregnant or breast feeding
Intervention: Ferric citrate
Trial phase: Not Applicable
ATC code: V03AE08
SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Fe+3]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 30
Group description: Participants randomized to the ferric citrate arm will receive 2 grams of ferric citrate three times a day with each meal.

ferric citrate: Participants randomized to the ferric citrate arm will take 2 grams of ferric citrate three times a day with meals.
Eligibility criteria:
Inclusion Criteria:

Age 18 years or greater
Moderate to severe CKD not requiring dialysis (eGFR 15 - 45 ml/min/1.73 m2 by CKD-EPI)
Absolute iron deficiency (serum ferritin <300ng/ml and Transferrin Saturation < 30%)

Exclusion Criteria:

Hemoglobin concentrations > 13 g/dL
Known disorder of iron homeostasis (e.g., hemochromatosis)
Known gastrointestinal disorder (irritable bowel disease, inflammatory bowel disease)
Known liver disease (ALT/AST or bilirubin > 3x normal)
Serum phosphorus concentrations < 3.0 mg/dL
Any known cause of anemia other than iron deficiency or CKD (e.g., sickle cell anemia)
Symptomatic gastrointestinal bleeding within 12 weeks prior to the screening visit.
Subjects receiving any form of renal replacement therapy including hemodialysis, peritoneal dialysis, or renal transplant.
Pregnancy or lactation in female participants
Severe anemia defined as a hemoglobin < 8.0 g/dL for males or a hemoglobin <7.0 g/dL for females.
Receipt of erythropoiesis stimulating agents within 4 weeks of screening.
Receipt of intravenous iron therapy within 8 weeks of screening.
Blood transfusion within 4 weeks of screening
Known allergies or severe adverse reactions to previous oral iron therapy
Current use of oral phosphorus binders.
Current use of an active vitamin D analog
Intervention: Ferrous Sulfate
Trial phase: Not Applicable
ATC code: B03AA07
SMILES: O=S(=O)([O-])[O-].[Fe+2]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 30
Group description: Participants randomized to the ferrous sulfate arm will receive 325 mg of ferrous sulfate three times a day

ferrous sulfate: Participants randomized to the ferrous sulfate arm will take 325 mg of ferrous sulfate three times a day.
Eligibility criteria:
Inclusion Criteria:

Age 18 years or greater
Moderate to severe CKD not requiring dialysis (eGFR 15 - 45 ml/min/1.73 m2 by CKD-EPI)
Absolute iron deficiency (serum ferritin <300ng/ml and Transferrin Saturation < 30%)

Exclusion Criteria:

Hemoglobin concentrations > 13 g/dL
Known disorder of iron homeostasis (e.g., hemochromatosis)
Known gastrointestinal disorder (irritable bowel disease, inflammatory bowel disease)
Known liver disease (ALT/AST or bilirubin > 3x normal)
Serum phosphorus concentrations < 3.0 mg/dL
Any known cause of anemia other than iron deficiency or CKD (e.g., sickle cell anemia)
Symptomatic gastrointestinal bleeding within 12 weeks prior to the screening visit.
Subjects receiving any form of renal replacement therapy including hemodialysis, peritoneal dialysis, or renal transplant.
Pregnancy or lactation in female participants
Severe anemia defined as a hemoglobin < 8.0 g/dL for males or a hemoglobin <7.0 g/dL for females.
Receipt of erythropoiesis stimulating agents within 4 weeks of screening.
Receipt of intravenous iron therapy within 8 weeks of screening.
Blood transfusion within 4 weeks of screening
Known allergies or severe adverse reactions to previous oral iron therapy
Current use of oral phosphorus binders.
Current use of an active vitamin D analog
Intervention: Victoza
Trial phase: Phase 3
ATC code: A10BJ02
SMILES: CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(Cc1ccccc1)C(=O)NC(C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C)C(C)CC)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 70
Group description: 7-week subcutaneous liraglutide treatment once daily

liraglutide: 7-week subcutaneous liraglutide once daily
Eligibility criteria:
Inclusion Criteria:

Signed informed consent.
Subjects between 40 and 65 years old. Diagnosis of type 2 diabetes mellitus with more than 5 years of evolution of disease.
Metformin (alone or in combination with sulfonylurea and / or insulin and / or thiazolidinediones) at a stable dose for at least the past 3 months.
HbA1c ≥ 7,0 y ≤ 9,0 %.
BMI between 30 and 40 kg / m2.
No pulmonary disease (COPD, asthma, fibrosis, etc) known.
Baseline FEV1 decline of equal or greater than 10% in the percentage of the theoretical value.
Chest radiography without significant changes in the lung parenchyma

Exclusion Criteria:

Type 1 diabetes mellitus
Treatment with inhibitors of dipeptidyl peptidase 4 glitazones and / or
SGLT2 inhibitors.
Active and former smokers for less than five years ago smoking.
Chronic obstructive pulmonary disease.
Respiratory sleep disorders that require treatment with continuous positive pressure in the airway.
Asthma treatment with bronchodilators.
Previous bariatric surgery.
Cardiovascular disease, heart failure and / or stroke.
Pathology of the chest wall.
Serum creatinine> 1.7 mg / dl.
Abnormal results in liver function test (Alanine transaminase/ Aspartate Aminotransferase greater than twice the upper limit of normal).
History of acute or chronic pancreatitis.
Personal or family history of medullary thyroid cancer or Multiple
Endocrine Neoplasia (MEN ) type 2.
Active neoplasms or neoplastic patients considered disease-free history from less than 5 years ago.
Women of childbearing age who are pregnant (positive pregnancy test within 14 days before the start of treatment) or intend to get pregnant.
Lactating women.
Women of childbearing potential not using adequate contraception (such as oral contraceptives, intrauterine device or barrier method of birth control along with spermicide or surgical sterilization) or unwilling to use during the study (as required by local laws or practices).
Intervention: Bupivacaine
Trial phase: Phase 3
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 16
Group description: Patients will receive a nerve block consisting of bupivacaine only.

Bupivacaine Only (control arm): Nerve blocks before surgery of L2-L4 and L4-S3 for Knee/Hip replacements
Eligibility criteria:
Inclusion Criteria:

Age between 18 and 85, and undergoing a total knee or hip replacement.
Fluent in English, decision competent, willing and able to provide written informed consent, and able to complete the study's schedule of assessments.
Able to walk >3m without an assisting device.
Have a BMI ≤ 40 kg/m2.

Exclusion Criteria:

Current participation in another orthopedic/Physical Therapy/rehab/anesthesiology interventional clinical trial.
Are at significant behavioral risks or have refractory major psychiatric disorders.
Revision surgery on the same extremity.
Have an American Surgical Association (ASA) Physical Status classification of 4 or higher.
Have been diagnosed with clinically significant neuropathy with its origins in either diabetes or other causes; have neuromuscular disease that would influence data collection.
Have a surgically-fused lumbar spine, or a spinal cord simulator, or other condition that would contraindicate or prohibit the conduct of spinal anesthesia.
At significant risk for postoperative substance abuse, or immediate-postoperative substance abuse withdrawal symptoms (alcohol, cocaine, enrolled in methadone or buprenorphine opioid withdrawal programs, etc.) Previous or current use of marijuana will not be an exclusion for study enrollment.
Are undergoing Total Knee Arthroplasty (TKA)/Total Hip Arthroplasty (THA) for a tumor.
Have contraindications (e.g., anaphylaxis) to any of the study drugs.
Have a systemic fungal infection.
Have a known hypersensitivity to bupivacaine hydrochloride or to any local anesthetic of the amide-type or to other components of bupivacaine hydrochloride solutions.
Have a known or suspected buprenorphine hypersensitivity (not including nausea and/or vomiting).
Have a gastro-intestinal (GI) obstruction.
Have paralytic ileus.
Pregnant women
Have had a kidney or liver transplant.

Veterans will not be excluded from participation based on smoking status, diagnosis of obstructive sleep apnea, or baseline monitored consumption of therapeutic opioids for documented medical indications; instead, these variables will be codified and quantified for subsequent covariate statistical analysis.
Intervention: Bupivacaine
Trial phase: Phase 2
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1
Group description: When the patient has been randomized to either group, a licensed provider under the direction of the PI, will utilize the ultrasound to identify the inferior tibiofibular ligament (syndesmotic ligament). This provider that performs the injection will not be involved in any follow-up visits or return to play review. When appropriate positioning is confirmed, the area will be injected with 5ml of bupivacaine hydrochloride.

bupivacaine hydrochloride: 5ml of bupivacaine hydrochloride into the tibiofibular ligament
Eligibility criteria:
Inclusion Criteria:

Age 16 years or older
Musculoskeletal ultrasound performed which demonstrates injury pattern consistent with high ankle sprain.
Must sign the informed consent form and agree to meet the needs of the study
Clinically and ultra sound confirmed and isolated syndesmotic ligament injury or high ankle sprain without associated fracture
Injury occurred within the previous 7 days

Exclusion Criteria:

Surgical intervention required to stabilize the ankle
Unable to read and understand the consent form
Unable to meet the needs of the follow-up examinations
Allergic to the betamethasone
Current fungal infection
Pregnancy or currently breast feeding
Intervention: Ropivacaine
Trial phase: Not Applicable
ATC code: N01BB09
SMILES: CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C
Sex: Female
Age groups: Child | Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 51
Group description: Patients will receive 0.5% Ropivacaine for the TAP block Procedure: Ultrasound guided TAP BLOCK Drug: 0.5% ropivacaine 20ml of 0.5% ropivacaine is used to perform the TAP block Other Names: •Naropin

Ropivacaine: Using 2 Different Concentrations of Ropivacaine in Tap Block for Postoperative Analgesia for C-Section Patients
Eligibility criteria:
Inclusion Criteria:

Pregnant patients undergoing elective c-section

Exclusion criteria:

Allergy to local anesthetics
Contraindication to tap blocks
Intervention: Ropivacaine
Trial phase: Not Applicable
ATC code: N01BB09
SMILES: CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C
Sex: Female
Age groups: Child | Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 51
Group description: Patients will receive 0.25% for the TAP block Procedure: ULTRASOUND GUIDED TAP BLOCK Drug: 0.25% ropivacaine 20ml of 0.25% ropivacaine is used to perform the TAP block Other Names: •Naropin

Ropivacaine: Using 2 Different Concentrations of Ropivacaine in Tap Block for Postoperative Analgesia for C-Section Patients
Eligibility criteria:
Inclusion Criteria:

Pregnant patients undergoing elective c-section

Exclusion criteria:

Allergy to local anesthetics
Contraindication to tap blocks